<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817618</url>
  </required_header>
  <id_info>
    <org_study_id>CLNP023B12301</org_study_id>
    <secondary_id>2020-004589-21</secondary_id>
    <nct_id>NCT04817618</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.</brief_title>
  <acronym>APPEAR-C3G</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a multicenter, randomized, double-blind, parallel group,&#xD;
      placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in&#xD;
      complement 3 glomerulopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to&#xD;
      placebo and standard of care in patients with native C3G. CLNP023B12301 is a Phase 3 pivotal&#xD;
      trial for registration of iptacopan in C3G. The study aims to determine the reduction in UPCR&#xD;
      and improvement in eGFR in participants treated with iptacopan compared to placebo, as well&#xD;
      as the proportion of participants who achieve a composite renal endpoint consisting of eGFR&#xD;
      and UPCR elements. These effects of iptacopan in conjunction with increases in serum C3&#xD;
      levels will provide support for an iptacopan profile that includes stabilization of eGFR,&#xD;
      clinically meaningful reductions in proteinuria and inhibition of the complement AP. Kidney&#xD;
      biopsies will be performed in all participants to evaluate histopathological improvements in&#xD;
      immunofluorescence and light microscopy that support these functional benefits of iptacopan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">August 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 24, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine collection).</measure>
    <time_frame>6 months (double-blind)</time_frame>
    <description>To demonstrate the superiority of iptacopan compared to placebo in reducing proteinuria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in eGFR.</measure>
    <time_frame>6 months (double-blind)</time_frame>
    <description>To demonstrate the superiority of iptacopan vs. placebo in improving eGFR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A participant meets the requirements of the composite renal endpoint if he/she satisfies: (1) a stable or improved eGFR compared to the baseline visit (≤15% reduction in eGFR), and (2) a ≥50% reduction in UPCR compared to the baseline visit.</measure>
    <time_frame>6 months (double-blind)</time_frame>
    <description>To demonstrate the superiority of iptacopan vs. placebo in the proportion of participants who meet the criteria for achieving a composite renal endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in disease total activity score in a renal biopsy.</measure>
    <time_frame>6 months (double-blind)</time_frame>
    <description>To demonstrate the effect of iptacopan vs placebo in reducing glomerular inflammation in the kidney.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score.</measure>
    <time_frame>6 months (double-blind)</time_frame>
    <description>To assess the effect of iptacopan compared to placebo in improvement of patient reported fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically significant vital signs, ECGs, and safety laboratory measurements, as well as adverse events, AEs of special interest, and study drug discontinuation due to an AE.</measure>
    <time_frame>6 month (double-blind)</time_frame>
    <description>To evaluate the safety and tolerability of iptacopan compared to placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>C3G</condition>
  <arm_group>
    <arm_group_label>iptacopan 200mg b.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to iptacopan 200mg b.i.d.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to iptacopan 200mg b.i.d.</description>
    <arm_group_label>Placebo to iptacopan 200mg b.i.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iptacopan</intervention_name>
    <description>iptacopan 200mg b.i.d.</description>
    <arm_group_label>iptacopan 200mg b.i.d.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants age ≥ 18 and ≤ 60 years at screening.&#xD;
&#xD;
          -  Diagnosis of C3G as confirmed by renal biopsy within 12 months prior to enrollment.&#xD;
&#xD;
          -  Prior to randomization, all participants must have been on a maximally recommended or&#xD;
             tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin&#xD;
             receptor blocker (ARB) for at least 90 days. The doses of other antiproteinuric&#xD;
             medications including mycophenolic acid, corticosteroids and mineralocorticoid&#xD;
             receptor antagonists should be stable for at least 90 days prior to randomization.&#xD;
&#xD;
          -  Reduced serum C3 (defined as less than 0.85 x lower limit of the central laboratory&#xD;
             normal range) at Screening.&#xD;
&#xD;
          -  UPCR ≥ 1.0 g/g sampled from the first morning void urine sample at Day -75 and Day&#xD;
             -15.&#xD;
&#xD;
          -  Estimated GFR (using the CKD-EPI formula) or measured GFR ≥ 30 ml/min/1.73m2 at&#xD;
             screening and Day -15.&#xD;
&#xD;
          -  Vaccination against Neisseria meningitidis infection prior to the start of study&#xD;
             treatment. Vaccination against Streptococcus pneumoniae and Haemophilus influenzae&#xD;
             infections should be given, if available and according to local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have received any cell or organ transplantation, including a kidney&#xD;
             transplantation.&#xD;
&#xD;
          -  Rapidly progressive crescentic glomerulonephritis defined as a 50% decline in the eGFR&#xD;
             within 3 months with renal biopsy findings of glomerular crescent formation seen in at&#xD;
             least 50% of glomeruli.&#xD;
&#xD;
          -  Renal biopsy showing interstitial fibrosis/tubular atrophy (IF/TA) of more than 50%.&#xD;
&#xD;
          -  Monoclonal gammopathy of undetermined significance (MGUS) confirmed by the measurement&#xD;
             of serum free light chains or other investigation as per local standard of care.&#xD;
&#xD;
          -  Participants with an active systemic bacterial, viral or fungal infection within 14&#xD;
             days prior to study treatment administration&#xD;
&#xD;
          -  The presence of fever ≥ 38°C (100.4°F) within 7 days prior to study treatment&#xD;
             administration.&#xD;
&#xD;
          -  A history of recurrent invasive infections caused by encapsulated organisms, e.g., N.&#xD;
             meningitidis and S. pneumoniae.&#xD;
&#xD;
          -  The use of inhibitors of complement factors (e.g., Factor B, Factor D, C3 inhibitors,&#xD;
             anti C5 antibodies, C5a receptor antagonists) within 6 months prior to the Screening&#xD;
             visit.&#xD;
&#xD;
          -  The use of immunosuppressants (except mycophenolic acids), cyclophosphamide or&#xD;
             systemic corticosteroids at a dose &gt;7.5 mg/day (or equivalent for a similar&#xD;
             medication) within 90 days of study drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille Cédex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ranica</city>
        <state>BG</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466 8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LNP023</keyword>
  <keyword>iptacopan</keyword>
  <keyword>C3G</keyword>
  <keyword>UPCR</keyword>
  <keyword>eGFR</keyword>
  <keyword>proteinuria</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

